2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.14 Clinical Outcomes of Neoadjuvant Immunotherapy in Stage I-II Non-Small Cell Lung Cancer: A Real-World Study and Meta-Analysis

EP.07C.14 Clinical Outcomes of Neoadjuvant Immunotherapy in Stage I-II Non-Small Cell Lung Cancer: A Real-World Study and Meta-Analysis

Back to course

Pdf Summary

The document presents findings from a real-world study and meta-analysis evaluating the efficacy of neoadjuvant immunotherapy (neoIO) combined with chemotherapy for patients with stage I-II non-small cell lung cancer (NSCLC). The study included 49 patients with an average age of 61.9 years, predominantly male, and most had the squamous subtype of NSCLC. Patients received PD-1 inhibitors, primarily in combination with chemotherapy. Results demonstrated an overall response rate (ORR) of 71.0% and a minimal invasive surgery R0 resection rate of 98.0%. The major pathologic response (MPR) rate was 59.2%, and the pathologic complete response (pCR) rate was 44.9%.<br /><br />The study highlights the oncological benefits of perioperative neoIO, especially neoadjuvant immunochemotherapy, which showed promising pathologic response rates despite significant heterogeneity when combined with other agents. Meta-analysis included 1,398 patients from six randomized controlled trials and 18 prospective studies, reporting pooled MPR and pCR rates. Subgroup analysis further supported the promising pathologic outcomes, with an MPR of 41.6% and pCR of 27.1% for neoadjuvant immunochemotherapy.<br /><br />The document underscores a need to gather more evidence on long-term outcomes and optimal regimens for neoIO in early-stage NSCLC, emphasizing its potential as a significant treatment evolution for resectable early-stage NSCLC. Future research directions should aim to address the heterogeneity observed in treatment outcomes and further refine neoadjuvant immunotherapy strategies.<br /><br />The study was conducted by researchers from the Guangdong Provincial People's Hospital and Zhongshan School of Medicine, supported by a comprehensive literature review and analysis registered in the PROSPERO database.

Asset Subtitle

Weijie Zhan

Meta Tag

Speaker Weijie Zhan

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neoadjuvant immunotherapy

NSCLC

stage I-II lung cancer

PD-1 inhibitors

chemotherapy

pathologic response rates

meta-analysis

oncological benefits

treatment evolution

PROSPERO database